AAPS PharmSciTech最新文献

{"title":"Chitosan-Based Nose-to-Brain Drug Delivery for Management of Neurological Disorders: Intrinsic Neuroprotective Action and Carrier Capabilities","authors":"Abhishek Singh,&nbsp;Sourin Bhukta,&nbsp;Deepak Mishra,&nbsp;Narahari N. Palei,&nbsp;Amita Verma,&nbsp;Lucy Mohapatra","doi":"10.1208/s12249-026-03563-8","DOIUrl":"10.1208/s12249-026-03563-8","url":null,"abstract":"<div><p>Neurological disorders represent a major global health burden, primarily due to the limited ability of therapeutic agents to cross the blood–brain barrier (BBB). Nose-to-brain (NTB) delivery has emerged as a promising non-invasive strategy to bypass the BBB and directly target the central nervous system (CNS). Among various polymers, chitosan has gained significant attention owing to its favourable physicochemical properties, biocompatibility, biodegradability, mucoadhesive nature, and ability to transiently open tight junctions of the nasal epithelium. This review comprehensively discusses the potential of chitosan-based systems for NTB delivery in the management of neurological disorders. The article outlines the physicochemical properties and biomedical applications of chitosan, followed by a detailed discussion of nasal anatomy and transport pathways involved in NTB drug delivery. The pharmacological aspects of chitosan in neurological disorders are highlighted, including its anti-oxidative, anti-neuroinflammatory, anti-apoptotic, anti-excitotoxic effects, suppression of β-amyloid accumulation, and acetylcholinesterase inhibitory activity. Various formulation approaches are critically reviewed, including chitosan-based nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, liposomes, microparticles, microspheres, and <i>in situ</i> gels designed for intranasal administration. Furthermore, surface-modified chitosan systems aimed at enhancing brain targeting are discussed, such as PEGylation, ligand-conjugated chitosan (transferrin and lactoferrin), cell-penetrating peptide functionalization, thiolated chitosan, and pH-sensitive derivatives including carboxymethyl and N-trimethyl chitosan. Comparative tables summarize formulation strategies, neurological indications, biological models, key outcomes, and reported findings. Overall, this review highlights the significant potential of chitosan and its surface-engineered derivatives as versatile carriers for NTB delivery in neurological disorders.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"27 7","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Folic Acid-Conjugated Solid Lipid Nanoparticles for Ratiometric Combination Delivery of Docetaxel and Erlotinib in Triple-Negative Breast Cancer Therapy","authors":"Aiswarya Chaudhuri,&nbsp;Dulla Naveen Kumar,&nbsp;Rohan Chand Sahu,&nbsp;Dinesh Kumar,&nbsp;Ashish Kumar Agrawal","doi":"10.1208/s12249-026-03561-w","DOIUrl":"10.1208/s12249-026-03561-w","url":null,"abstract":"<div><p>Triple-negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options and poor clinical outcomes. This study evaluated folic acid-functionalized solid lipid nanoparticles co-loaded with docetaxel and erlotinib (FA-DOC/ERL-SLNs) as an oral targeted therapy for TNBC. FA-DOC/ERL-SLNs exhibited the lowest IC₅₀ values of 0.82 ± 0.05 μM and 0.92 ± 0.03 μM in MDA-MB-231 and 4T1 cells, respectively, with enhanced cellular uptake compared with free drugs and non-targeted SLNs. The formulation also induced higher apoptosis (apoptosis indices of 1.42 and 1.45), greater G2/M cell-cycle arrest, autophagy inhibition, and reduced clonogenicity and migration. Pharmacokinetic studies demonstrated markedly improved oral bioavailability, with AUC₀–t increasing from 1.03 to 45.69 μg·h/mL for docetaxel and from 18.30 to 87.76 μg·h/mL for erlotinib. In 4T1 tumor-bearing mice, FA-DOC/ERL-SLNs reduced tumor volume by approximately 1.5-fold compared with non-targeted SLNs and 2.5–3.0-fold compared with free drugs, without significant body weight loss or systemic toxicity. These findings demonstrate that FA-DOC/ERL-SLNs enhance the efficacy and safety of oral docetaxel–erlotinib combination therapy and represent a promising targeted nanocarrier platform for TNBC treatment.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"27 7","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality-by-design Driven Formulation Development of Propellent Free Foam Formulation for Effective Burn-related Wound Healing: A Comprehensive Preclinical Study","authors":"Mohit Kumar,&nbsp;Devesh Kumar,&nbsp;Jailani Shiekmydeen,&nbsp;Shubham Upadhayay,&nbsp;Puneet Kumar,&nbsp;Shruti Chopra,&nbsp;Amit Bhatia","doi":"10.1208/s12249-026-03564-7","DOIUrl":"10.1208/s12249-026-03564-7","url":null,"abstract":"<div><p>Burn wound infections remain a major clinical challenge due to extensive tissue damage, delayed healing, and increased susceptibility to microbial contamination, which can limit the effectiveness of conventional topical formulations. This study aimed to develop and optimize a Quality-by-Design (QbD)-based non-propellant foam (NPF) containing silver nitrate, chlorhexidine, and asiaticoside for enhanced burn wound management. A sequential design of experiments strategy was employed, involving Taguchi L8 screening followed by Box–Behnken optimization to identify the critical formulation variables influencing foam performance and drug release. The optimized formulation exhibited desirable physicochemical characteristics, including a foam density of 0.192 ± 0.002 g/mL, a skin-compatible pH of 5.56 ± 0.04, uniform drug content (98–99%), and satisfactory foam stability. <i>In-vitro</i> studies demonstrated cumulative drug release of 94.69% chlorhexidine, 82.13% asiaticoside, and 78.63% silver nitrate within 6 h, with the release profiles predominantly following the Higuchi diffusion model. Accelerated stability studies indicated that the formulation remained stable over six months. In a Sprague–Dawley rat burn wound model, the optimized foam achieved 93.29 ± 1.75% wound contraction by day 14, outperforming both the untreated control and the marketed formulation. Furthermore, biochemical analyses revealed increased hydroxyproline, hexosamine, and hexuronic acid levels, while histopathological examination confirmed enhanced collagen deposition, neovascularization, and re-epithelialization. These findings demonstrate that the developed QbD-based non-propellant foam represents a promising preclinical topical delivery platform capable of supporting both antimicrobial protection and tissue repair during burn wound healing.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"27 7","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitigating the Resolution-Field of View Trade-Off for Comprehensive Microstructural Characterization with Advanced AI Methods","authors":"Aawaz Raj Pokhrel,&nbsp;Jayanti Das,&nbsp;Boren Ke,&nbsp;Lisa Ma,&nbsp;Shawn Zhang,&nbsp;Maxwell Korang-Yeboah","doi":"10.1208/s12249-026-03558-5","DOIUrl":"10.1208/s12249-026-03558-5","url":null,"abstract":"<div><p>Microstructural characterization of pharmaceutical drug products is essential for understanding process–microstructure–performance relationships and ensuring consistent product quality. However, quantitative characterization is limited by a trade-off between imaging resolution and field of view: high-resolution imaging captures fine structural detail but over small sample volumes, whereas lower-resolution imaging provides broader coverage while missing critical morphological features. To address this limitation, we developed and validated an integrated framework combining convolutional neural network (CNN)-based super-resolution with Generative Adversarial Network (GAN)-based microstructure synthesis. Lyophilized drug products imaged by X-ray microscopy at multiple resolutions served as the model system. We first demonstrated that imaging resolution is a governing factor in quantitative microstructural analysis: mean pore size showed a coefficient of variation of 40.2% across resolution levels, compared with only 0.47% attributable to spatial heterogeneity within the same sample. CNN-based upscaling using ESRGAN/BSRGAN recovered solid-wall structures and pore-size distributions lost after downsampling and restored effective diffusivity toward values measured in the original high-resolution data. In an independent validation using a separate formulation imaged at 5 and 10 µm per voxel, the upscaled images reproduced pore-size distributions and diffusivity profiles closer to the 5 µm reference and showed better recovery of CQA-relevant structural features than conventional bicubic interpolation, despite lower pixel-level image fidelity scores. GAN-based synthesis expanded the field of view four-fold from a small high-resolution seed region while preserving pore-size distributions and transport properties. Together, these findings demonstrate a scalable approach for improving microstructural characterization under practical imaging constraints.</p></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"27 7","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transdermal Transport of a Geometric Self-Oscillating Copper Nanosystem for Topical Treatment of Psoriasis","authors":"Karmani Murugan,&nbsp;Pradeep Kumar,&nbsp;Lisa C. du Toit,&nbsp;Poornima Ramburrun,&nbsp;Yahya E. Choonara","doi":"10.1208/s12249-026-03549-6","DOIUrl":"10.1208/s12249-026-03549-6","url":null,"abstract":"<div><p>Neogeometric copper nanoparticles (CuNPs) in drug delivery can be exploited for its cytotoxic effects and enhanced cellular uptake in dermatological conditions. The nanosystem, designed herein, is embedded in a Self-Oscillating Polymeric Network (SOPN) to stimulate the permeation of cubic CuNPs across the stratum corneum of induced psoriasiform-plaques in a BALB/c mouse model. Polymerization and cross-linking of the SOPN from NIPAM (N-isopropylacrylamide) and a metal salt exerted thermal and molecular differences of the resulting poly-NIPAM whilst maintaining inherent NIPAM thermo-responsive properties to control CuNP-permeation in an inflammatory environment. From an experimental design consisting of 15 formulations, it was found that thermo-responsive changes between 27–35˚C in the SOPN promoted the oscillatory behavior required for skin permeation of CuNPs where an oscillatory duration of 40 min was obtained. Viability analysis of the SOPN established biocompatible concentrations of the system for use in the <i>in vivo</i> model at reduced CuNP concentrations to control cytotoxicity (64.26–72.58%). The CuNP-loaded SOPN gel (60ug/mL) effectively promoted psoriatic-plaque resolution and hair growth, after 7 and 14 days of treatment, compared to the comparative (0.5% hydrocortisone cream). The geometric nanosystem embedded in an aqueous cream vehicle and the SOPN gel exhibited promising results in the reduction of <i>in vivo</i> psoriasiform-plaques compared to the gold standard.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"27 7","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1208/s12249-026-03549-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating Surfactant Selection in In Vitro Dissolution Testing: Mechanistic Insights and Practical Strategies","authors":"Sushesh Srivatsa Palakurthi,&nbsp;Niloufar Salehi,&nbsp;Jie Shen,&nbsp;Sanjaykumar Patel,&nbsp;Nikoletta Fotaki,&nbsp;Deanna Mudie,&nbsp;Sumedha Kapre,&nbsp;Pradnya Bapat,&nbsp;Christopher Rego,&nbsp;David B. Turner,&nbsp;Omid Arjmandi-Tash,&nbsp;Zizhao Xu,&nbsp;Shriram M. Pathak,&nbsp;Karina I. Vazquez,&nbsp;Vivian Gray","doi":"10.1208/s12249-026-03552-x","DOIUrl":"10.1208/s12249-026-03552-x","url":null,"abstract":"<div><p><i>In vitro</i> dissolution testing is central to pharmaceutical development, yet it is increasingly challenged by poorly soluble drugs, which account for over 40% of marketed products and up to 90% of new chemical entities, for which dissolution often limits absorption. Surfactants are widely incorporated into dissolution media to achieve sink conditions and improve the discriminatory powder of dissolution methods, but inappropriate surfactant selection or concentration can alter drug release mechanisms, mask formulation differences, and reduce biopredictive performance. This review examines the mechanisms of surfactant action, including wetting enhancement, micellar solubilization, and drug-surfactant interactions, together with the physicochemical properties of anionic, cationic, non-ionic, and zwitterionic surfactant relevant to dissolution testing. Building on these principles, we discuss practical considerations for surfactant selection, concentration optimization, analytical compatibility, surfactant quality and source variability, formulation-specific considerations for enabled drug delivery systems, integration with physiologically based biopharmaceutics modeling, and evolving regulatory expectations. Together, these provide a practical framework for developing robust, reproducible, and discriminating dissolution methods that better reflect <i>in vivo</i> performance and support decision-making across drug development.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"27 7","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1208/s12249-026-03552-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis and Optimization of PEG-PLGA Immunotherapeutic Nanoparticles for the Controlled Release of IFNα","authors":"Magdi E. A. Abobaker,&nbsp;Mershen Govender,&nbsp;Yahya E. Choonara","doi":"10.1208/s12249-026-03548-7","DOIUrl":"10.1208/s12249-026-03548-7","url":null,"abstract":"<div><p>The therapeutic efficacy of interferon alpha (IFNα) is well-established in various conditions, including Hepatitis B and C, lymphoma and skin cancer, attributed to its potent angiostatic, immunomodulatory, and antiproliferative properties. Clinical applications using this bioactive are, however, hindered by systemic toxicity due to the high doses used, increasing costs and reducing patient adherence. The use of a controlled-release polymeric nanoparticulate system that can potentially decrease the administered dose, and therefore the associated costs, may additionally improve overall patient acceptability without affecting therapeutic efficacy. This study provides for the development, statistical optimization and characterization of poly(lactic-co-glycolic acid) nanoparticles (PLGANPs) for the controlled release of IFNα. A double-emulsion solvent evaporation method was employed for nanoparticle (NP) synthesis, with formulation optimization achieved through a Central Composite Design (CCD) approach to ensure adequate size, stability, and sustained release over five days. Characterization of the optimized IFNα-PLGANPs using dynamic light scattering, zeta potential analysis, scanning electron microscopy (SEM), thermogravimetric analysis (TGA), and drug release studies at pH 7.2 displayed an average particle size of 97.03 nm (PDI = 0.182), zeta potential of − 34.10 mV and a maximum drug release of 5 days, with morphological analysis revealing the formation of spherical NPs with a smooth surface topology, confirming the homogeneity and structural stability of the formulation. These findings underscore the potential of the developed PLGANPs as a suitable platform for the controlled release of IFNα, noting the use of advanced nanotechnology-driven solutions to overcome the limitations of conventional therapies.</p></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"27 7","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1208/s12249-026-03548-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Strategic Formulation to Enhance the Safety and Anti-Hyperlipidaemic Activity of Simvastatin: Prototype Development","authors":"Arka Karmakar,&nbsp;Varla Yalamanda,&nbsp;Yogesh Khairnar,&nbsp;Subhrasima Nayak,&nbsp;Lalit Kumar,&nbsp;Md. Abubakar,&nbsp;Nitesh Kumar","doi":"10.1208/s12249-026-03523-2","DOIUrl":"10.1208/s12249-026-03523-2","url":null,"abstract":"<div><p>Statins are widely regarded as the gold standard first-line treatment for hyperlipidemia, as they inhibit HMG-CoA reductase in the liver. This effectively reduces LDL cholesterol levels and reduces cardiovascular risks, such as heart attack and stroke. Simvastatin is a well-established, effective, and cost-efficient statin for lowering LDL cholesterol and reducing cardiovascular risk. However, it causes myopathy, rhabdomyolysis, myalgia, constipation, kidney failure, headache, abdominal pain, diarrhoea, nausea, and increased blood sugar levels with its use and higher doses of 80 mg/day. To address this, a liposomal simvastatin formulation with particle sizes of 150–250 nm was developed for intravenous administration. This formulation can potentially accumulate in the liver via passive targeting via the RES, thereby enhancing hepatic uptake and improving safety. The liposome was formulated using the thin-film hydration method and optimised using a central composite design. The optimized formulation's vesicle size was 204.66 ± 2.84 nm, with a PDI of 0.27 and a zeta potential of -58.11 mV, indicating uniform distribution and high stability. <i>In-vitro</i> drug release demonstrated controlled release of up to 92.46% over 60 h. The cellular toxicity assay showed that the optimized liposome was 10 times safer than pure simvastatin. <i>In-vivo</i>, the liposomal formulation significantly reduced lipid levels after administration of a 5 mg/kg dose in Triton X-100-induced hyperlipidemic rats, outperforming marketed formulations and standard drugs. Simvastatin-liposomes are safe, stable, and a more potent alternative to traditional oral simvastatin, offering improved liver targeting and a reduced toxicity profile.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"27 7","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients In-Use Stability and Safety of Repacked Delayed-Release Tablets of a Narrow Therapeutic Index Antiseizure Agent","authors":"Mariame A. Hassan,&nbsp;Bhanu Prakash Dongala,&nbsp;Annette DeSantiago,&nbsp;Ziyaur Rahman,&nbsp;Mansoor A. Khan","doi":"10.1208/s12249-026-03510-7","DOIUrl":"10.1208/s12249-026-03510-7","url":null,"abstract":"<div><p>Divalproex Sodium (DVS) is an antiepileptic agent with a narrow therapeutic window and a wide range of side effects. Its delayed-release forms demonstrated better tolerability in terms of gastrointestinal side effects. DVS has high sensitivity to temperature and humidity. Owing to a high frequency of daily administration, outpatients may keep their medication supply accessible in places that might not qualify for proper drug storage. In this study, five FDA-approved DVS delayed-release tablet products (A-E) were assessed for physical integrity, physicochemical changes and drug release pattern before and after repackaging in amber-colored closed pharmacy vials and storage at 30°C/75%RH. Initially, one product showed dissimilarity to the others (<i>f1</i> = 19.6, <i>f2</i> = 41.6). Upon storage, tablets showed signs of physical damage after 1 month. At 3 months, A, B and E tablets lost their integrity completely. Product C displayed high variability in acid (44.9 ± 31.5% drug release). Tablets that remained intact after storage failed the <i>f1</i> and <i>f2</i> tests. The images showed evidence of chemical changes in all products. The results indicated that repackaging and improper in-use keep could result in unpredictable drug release. It is debated that the total daily systemic bioavailability of DVS, rather than the peak-to-trough differences, is the primary determinant of seizure control. However, variability in drug release can result in gastric irritation, systemic side effects, drug intolerance and patients’ noncompliance. This unnecessary burdening of the health care system can be avoided when revising dispensing and storage recommendations of DVS products.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"27 7","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1208/s12249-026-03510-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Throughput eSWIR Hyperspectral Imaging for Pharmaceutical Classification at Industrial Line Speeds","authors":"Siamak Kashi,&nbsp;Yongjin Sung","doi":"10.1208/s12249-026-03557-6","DOIUrl":"10.1208/s12249-026-03557-6","url":null,"abstract":"<div><p>Real-time quality control of pharmaceutical dosage forms requires rapid, non-destructive analytical technologies that provide chemical specificity while maintaining high throughput. Here, an extended short-wave infrared (eSWIR, 1000–2500 nm) line-scan hyperspectral imaging system (L-EOS 2.5e, Photon Etc.) was evaluated for spatially resolved classification of pharmaceutical tablets. The system was evaluated at integration times of 2, 0.2, and 0.02 ms using Standard Normal Variate normalization, Savitzky–Golay second-derivative preprocessing, and an error-correcting output codes support vector machine classifier. Product-level classification of 11 pharmaceutical products achieved accuracies of 99.99%, 100%, and 97.6% at 2, 0.2, and 0.02 ms, respectively. A more challenging manufacturer-level discrimination task involving three 500 mg acetaminophen products containing the same active pharmaceutical ingredient and labeled dose achieved accuracies of 99.7%, 98.6%, and 89.3% at the corresponding integration times. These results demonstrate the potential of eSWIR hyperspectral imaging for rapid, spatially resolved pharmaceutical product discrimination and high-throughput inspection.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"27 7","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1208/s12249-026-03557-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}